Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Bristol Myers Squibb today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi ® in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Bristol Myers Squibb today announced the U.S. Food and Drug Administration has granted accelerated approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the ...

BREYANZI can increase the risk of life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

When your BREYANZI is ready, your healthcare provider will give it to you through a catheter placed into your vein (intravenous infusion). BREYANZI is given as infusions of 2 different cell types.

Key Takeaways Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a ...

Breyanzi carries a Boxed Warning regarding the risk for cytokine release syndrome and neurologic toxicities including fatal or life-threatening reactions. It is available only through a restricted ...

Breyanzi is also indicated for the treatment of large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.